APO Research
Talk to an analyst

APO RESEARCH · REPORT

T Cell Surface Glycoprotein CD3 Epsilon

Compare research editions
View pricing & licenses

Selected research

Industry Research

T Cell Surface Glycoprotein CD3 Epsilon Industry Research Report 2026

19 December 2025115 pages

Choose your research edition.

Industry ResearchT Cell Surface Glycoprotein CD3 Epsilon Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal T Cell Surface Glycoprotein CD3 Epsilon Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal T Cell Surface Glycoprotein CD3 Epsilon Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal T Cell Surface Glycoprotein CD3 Epsilon Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal T Cell Surface Glycoprotein CD3 Epsilon Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global T Cell Surface Glycoprotein CD3 Epsilon market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the T Cell Surface Glycoprotein CD3 Epsilon market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the T Cell Surface Glycoprotein CD3 Epsilon market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the T Cell Surface Glycoprotein CD3 Epsilon market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of T Cell Surface Glycoprotein CD3 Epsilon include GlaxoSmithKline Plc, Amgen Inc, Tiziana Life Sciences Plc, SYNIMMUNE GmbH, Numab Innovation AG, Meridigen Biotech Co Ltd, MacroGenics Inc, F. Hoffmann-La Roche Ltd and Celgene Corp. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global T Cell Surface Glycoprotein CD3 Epsilon market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to T Cell Surface Glycoprotein CD3 Epsilon.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

T Cell Surface Glycoprotein CD3 Epsilon Market by Company

GlaxoSmithKline Plc

Amgen Inc

Tiziana Life Sciences Plc

SYNIMMUNE GmbH

Numab Innovation AG

Meridigen Biotech Co Ltd

MacroGenics Inc

F. Hoffmann-La Roche Ltd

Celgene Corp

T Cell Surface Glycoprotein CD3 Epsilon Segment by Type

ND-007

Foralumab

Coltelizumab

AVA-002

Others

T Cell Surface Glycoprotein CD3 Epsilon Segment by Application

Autoimmune Disorders

Hepatitis B

Prostate Cancer

Multiple Sclerosis

Others

T Cell Surface Glycoprotein CD3 Epsilon Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global T Cell Surface Glycoprotein CD3 Epsilon market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of T Cell Surface Glycoprotein CD3 Epsilon and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of T Cell Surface Glycoprotein CD3 Epsilon.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of T Cell Surface Glycoprotein CD3 Epsilon companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size by Type (2021-2026) & (US$ Million) Table 6. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Type (2021-2026) Table 7. Global T Cell Surface Glycoprotein CD3 Epsilon Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Type (2027-2032) Table 9. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size by Application (2021-2026) & (US$ Million) Table 10. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Application (2021-2026) Table 11. Global T Cell Surface Glycoprotein CD3 Epsilon Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Application (2027-2032) Table 13. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size by Region (2021-2026) & (US$ Million) Table 15. Global T Cell Surface Glycoprotein CD3 Epsilon Market Share by Region (2021-2026) Table 16. Global T Cell Surface Glycoprotein CD3 Epsilon Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global T Cell Surface Glycoprotein CD3 Epsilon Market Share by Region (2027-2032) Table 18. T Cell Surface Glycoprotein CD3 Epsilon Industry Trends Table 19. T Cell Surface Glycoprotein CD3 Epsilon Industry Drivers Table 20. T Cell Surface Glycoprotein CD3 Epsilon Industry Opportunities and Challenges Table 21. T Cell Surface Glycoprotein CD3 Epsilon Market Restraints Table 22. Global Top T Cell Surface Glycoprotein CD3 Epsilon Players by Revenue (US$ Million) & (2021-2026) Table 23. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Players (2021-2026) Table 24. Global T Cell Surface Glycoprotein CD3 Epsilon Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of T Cell Surface Glycoprotein CD3 Epsilon, Headquarters and Area Served Table 26. Global T Cell Surface Glycoprotein CD3 Epsilon Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global T Cell Surface Glycoprotein CD3 Epsilon by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America T Cell Surface Glycoprotein CD3 Epsilon Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2021-2026) & (US$ Million) Table 32. North America T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe T Cell Surface Glycoprotein CD3 Epsilon Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific T Cell Surface Glycoprotein CD3 Epsilon Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific T Cell Surface Glycoprotein CD3 Epsilon Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2027-2032) & (US$ Million) Table 39. South America T Cell Surface Glycoprotein CD3 Epsilon Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2021-2026) & (US$ Million) Table 41. South America T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2027-2032) & (US$ Million) Table 45. GlaxoSmithKline Plc Company Information Table 46. GlaxoSmithKline Plc Business Overview Table 47. GlaxoSmithKline Plc Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) & (US$ Million) Table 48. GlaxoSmithKline Plc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 49. GlaxoSmithKline Plc Recent Developments Table 50. Amgen Inc Company Information Table 51. Amgen Inc Business Overview Table 52. Amgen Inc Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) & (US$ Million) Table 53. Amgen Inc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 54. Amgen Inc Recent Developments Table 55. Tiziana Life Sciences Plc Company Information Table 56. Tiziana Life Sciences Plc Business Overview Table 57. Tiziana Life Sciences Plc Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) & (US$ Million) Table 58. Tiziana Life Sciences Plc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 59. Tiziana Life Sciences Plc Recent Developments Table 60. SYNIMMUNE GmbH Company Information Table 61. SYNIMMUNE GmbH Business Overview Table 62. SYNIMMUNE GmbH Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) & (US$ Million) Table 63. SYNIMMUNE GmbH T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 64. SYNIMMUNE GmbH Recent Developments Table 65. Numab Innovation AG Company Information Table 66. Numab Innovation AG Business Overview Table 67. Numab Innovation AG Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) & (US$ Million) Table 68. Numab Innovation AG T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 69. Numab Innovation AG Recent Developments Table 70. Meridigen Biotech Co Ltd Company Information Table 71. Meridigen Biotech Co Ltd Business Overview Table 72. Meridigen Biotech Co Ltd Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) & (US$ Million) Table 73. Meridigen Biotech Co Ltd T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 74. Meridigen Biotech Co Ltd Recent Developments Table 75. MacroGenics Inc Company Information Table 76. MacroGenics Inc Business Overview Table 77. MacroGenics Inc Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) & (US$ Million) Table 78. MacroGenics Inc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 79. MacroGenics Inc Recent Developments Table 80. F. Hoffmann-La Roche Ltd Company Information Table 81. F. Hoffmann-La Roche Ltd Business Overview Table 82. F. Hoffmann-La Roche Ltd Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) & (US$ Million) Table 83. F. Hoffmann-La Roche Ltd T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 84. F. Hoffmann-La Roche Ltd Recent Developments Table 85. Celgene Corp Company Information Table 86. Celgene Corp Business Overview Table 87. Celgene Corp Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) & (US$ Million) Table 88. Celgene Corp T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 89. Celgene Corp Recent Developments Table 90. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. T Cell Surface Glycoprotein CD3 Epsilon Product Image Figure 5. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global T Cell Surface Glycoprotein CD3 Epsilon Market Share by Type: 2025 VS 2032 Figure 7. ND-007 Product Figure 8. Foralumab Product Figure 9. Coltelizumab Product Figure 10. AVA-002 Product Figure 11. Others Product Figure 12. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global T Cell Surface Glycoprotein CD3 Epsilon Market Share by Application: 2025 VS 2032 Figure 14. Autoimmune Disorders Product Figure 15. Hepatitis B Product Figure 16. Prostate Cancer Product Figure 17. Multiple Sclerosis Product Figure 18. Others Product Figure 19. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 20. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 21. Global T Cell Surface Glycoprotein CD3 Epsilon Market Share by Region: 2025 VS 2032 Figure 22. Global T Cell Surface Glycoprotein CD3 Epsilon Market Share by Players in 2025 Figure 23. Global T Cell Surface Glycoprotein CD3 Epsilon Manufacturers Established Date Figure 24. Global Top 5 and 10 T Cell Surface Glycoprotein CD3 Epsilon Players Market Share by Revenue in 2025 Figure 25. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. North America T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. North America T Cell Surface Glycoprotein CD3 Epsilon Market Share by Country (2021-2032) Figure 28. United States T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Canada T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. Mexico T Cell Surface Glycoprotein CD3 Epsilon Market Share by Country (2021-2032) Figure 31. Europe T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe T Cell Surface Glycoprotein CD3 Epsilon Market Share by Country (2021-2032) Figure 33. Germany T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. France T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. U.K. T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Italy T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Spain T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 38. Russia T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Netherlands T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. Nordic Countries T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. Asia-Pacific T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. Asia-Pacific T Cell Surface Glycoprotein CD3 Epsilon Market Share by Country (2021-2032) Figure 43. China T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. Japan T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. South Korea T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. India T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. India T Cell Surface Glycoprotein CD3 Epsilon Market Share by Country (2021-2032) Figure 48. Australia T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. China Taiwan T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Southeast Asia T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. South America T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. South America T Cell Surface Glycoprotein CD3 Epsilon Market Share by Country (2021-2032) Figure 53. Brazil T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 54. Argentina T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 55. Chile T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 56. Colombia T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 57. Peru T Cell Surface Glycoprotein CD3 Epsilon Market Size YoY Growth (2021-2032) & (US$ Million) Figure 58. GlaxoSmithKline Plc Revenue Growth Rate in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) Figure 59. Amgen Inc Revenue Growth Rate in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) Figure 60. Tiziana Life Sciences Plc Revenue Growth Rate in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) Figure 61. SYNIMMUNE GmbH Revenue Growth Rate in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) Figure 62. Numab Innovation AG Revenue Growth Rate in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) Figure 63. Meridigen Biotech Co Ltd Revenue Growth Rate in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) Figure 64. MacroGenics Inc Revenue Growth Rate in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) Figure 65. F. Hoffmann-La Roche Ltd Revenue Growth Rate in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026) Figure 66. Celgene Corp Revenue Growth Rate in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026)

Scope & coverage.

Types
  • ND-007
  • Foralumab
  • Coltelizumab
  • AVA-002
  • Others
Applications
  • Autoimmune Disorders
  • Hepatitis B
  • Prostate Cancer
  • Multiple Sclerosis
  • Others
Companies covered
  • GlaxoSmithKline Plc
  • Amgen Inc
  • Tiziana Life Sciences Plc
  • SYNIMMUNE GmbH
  • Numab Innovation AG
  • Meridigen Biotech Co Ltd
  • MacroGenics Inc
  • F. Hoffmann-La Roche Ltd
  • Celgene Corp

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 T Cell Surface Glycoprotein CD3 Epsilon by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 ND-007
  5. 2.2.3 Foralumab
  6. 2.2.4 Coltelizumab
  7. 2.2.5 AVA-002
  8. 2.2.6 Others
  9. 2.3 T Cell Surface Glycoprotein CD3 Epsilon by Application
  10. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  11. 2.3.2 Autoimmune Disorders
  12. 2.3.3 Hepatitis B
  13. 2.3.4 Prostate Cancer
  14. 2.3.5 Multiple Sclerosis
  15. 2.3.6 Others
  16. 2.4 Assumptions and Limitations
3 T Cell Surface Glycoprotein CD3 Epsilon Breakdown Data by Type
  1. 3.1 Global T Cell Surface Glycoprotein CD3 Epsilon Historic Market Size by Type (2021-2026)
  2. 3.2 Global T Cell Surface Glycoprotein CD3 Epsilon Forecasted Market Size by Type (2027-2032)
4 T Cell Surface Glycoprotein CD3 Epsilon Breakdown Data by Application
  1. 4.1 Global T Cell Surface Glycoprotein CD3 Epsilon Historic Market Size by Application (2021-2026)
  2. 4.2 Global T Cell Surface Glycoprotein CD3 Epsilon Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global T Cell Surface Glycoprotein CD3 Epsilon Market Perspective (2021-2032)
  2. 5.2 Global T Cell Surface Glycoprotein CD3 Epsilon Growth Trends by Region
  3. 5.2.1 Global T Cell Surface Glycoprotein CD3 Epsilon Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 T Cell Surface Glycoprotein CD3 Epsilon Historic Market Size by Region (2021-2026)
  5. 5.2.3 T Cell Surface Glycoprotein CD3 Epsilon Forecasted Market Size by Region (2027-2032)
  6. 5.3 T Cell Surface Glycoprotein CD3 Epsilon Market Dynamics
  7. 5.3.1 T Cell Surface Glycoprotein CD3 Epsilon Industry Trends
  8. 5.3.2 T Cell Surface Glycoprotein CD3 Epsilon Market Drivers
  9. 5.3.3 T Cell Surface Glycoprotein CD3 Epsilon Market Challenges
  10. 5.3.4 T Cell Surface Glycoprotein CD3 Epsilon Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top T Cell Surface Glycoprotein CD3 Epsilon Players by Revenue
  2. 6.1.1 Global Top T Cell Surface Glycoprotein CD3 Epsilon Players by Revenue (2021-2026)
  3. 6.1.2 Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Market Share by Players (2021-2026)
  4. 6.2 Global T Cell Surface Glycoprotein CD3 Epsilon Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of T Cell Surface Glycoprotein CD3 Epsilon Head Office and Area Served
  6. 6.4 Global T Cell Surface Glycoprotein CD3 Epsilon Players, Product Type & Application
  7. 6.5 Global T Cell Surface Glycoprotein CD3 Epsilon Manufacturers Established Date
  8. 6.6 Global T Cell Surface Glycoprotein CD3 Epsilon Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America T Cell Surface Glycoprotein CD3 Epsilon Market Size (2021-2032)
  2. 7.2 North America T Cell Surface Glycoprotein CD3 Epsilon Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2021-2026)
  4. 7.4 North America T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe T Cell Surface Glycoprotein CD3 Epsilon Market Size (2021-2032)
  2. 8.2 Europe T Cell Surface Glycoprotein CD3 Epsilon Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2021-2026)
  4. 8.4 Europe T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific T Cell Surface Glycoprotein CD3 Epsilon Market Size (2021-2032)
  2. 9.2 Asia-Pacific T Cell Surface Glycoprotein CD3 Epsilon Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America T Cell Surface Glycoprotein CD3 Epsilon Market Size (2021-2032)
  2. 10.2 South America T Cell Surface Glycoprotein CD3 Epsilon Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2021-2026)
  4. 10.4 South America T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Market Size (2021-2032)
  2. 11.2 Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 GlaxoSmithKline Plc
  2. 12.1.1 GlaxoSmithKline Plc Company Information
  3. 12.1.2 GlaxoSmithKline Plc Business Overview
  4. 12.1.3 GlaxoSmithKline Plc Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026)
  5. 12.1.4 GlaxoSmithKline Plc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  6. 12.1.5 GlaxoSmithKline Plc Recent Developments
  7. 12.2 Amgen Inc
  8. 12.2.1 Amgen Inc Company Information
  9. 12.2.2 Amgen Inc Business Overview
  10. 12.2.3 Amgen Inc Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026)
  11. 12.2.4 Amgen Inc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  12. 12.2.5 Amgen Inc Recent Developments
  13. 12.3 Tiziana Life Sciences Plc
  14. 12.3.1 Tiziana Life Sciences Plc Company Information
  15. 12.3.2 Tiziana Life Sciences Plc Business Overview
  16. 12.3.3 Tiziana Life Sciences Plc Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026)
  17. 12.3.4 Tiziana Life Sciences Plc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  18. 12.3.5 Tiziana Life Sciences Plc Recent Developments
  19. 12.4 SYNIMMUNE GmbH
  20. 12.4.1 SYNIMMUNE GmbH Company Information
  21. 12.4.2 SYNIMMUNE GmbH Business Overview
  22. 12.4.3 SYNIMMUNE GmbH Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026)
  23. 12.4.4 SYNIMMUNE GmbH T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  24. 12.4.5 SYNIMMUNE GmbH Recent Developments
  25. 12.5 Numab Innovation AG
  26. 12.5.1 Numab Innovation AG Company Information
  27. 12.5.2 Numab Innovation AG Business Overview
  28. 12.5.3 Numab Innovation AG Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026)
  29. 12.5.4 Numab Innovation AG T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  30. 12.5.5 Numab Innovation AG Recent Developments
  31. 12.6 Meridigen Biotech Co Ltd
  32. 12.6.1 Meridigen Biotech Co Ltd Company Information
  33. 12.6.2 Meridigen Biotech Co Ltd Business Overview
  34. 12.6.3 Meridigen Biotech Co Ltd Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026)
  35. 12.6.4 Meridigen Biotech Co Ltd T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  36. 12.6.5 Meridigen Biotech Co Ltd Recent Developments
  37. 12.7 MacroGenics Inc
  38. 12.7.1 MacroGenics Inc Company Information
  39. 12.7.2 MacroGenics Inc Business Overview
  40. 12.7.3 MacroGenics Inc Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026)
  41. 12.7.4 MacroGenics Inc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  42. 12.7.5 MacroGenics Inc Recent Developments
  43. 12.8 F. Hoffmann-La Roche Ltd
  44. 12.8.1 F. Hoffmann-La Roche Ltd Company Information
  45. 12.8.2 F. Hoffmann-La Roche Ltd Business Overview
  46. 12.8.3 F. Hoffmann-La Roche Ltd Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026)
  47. 12.8.4 F. Hoffmann-La Roche Ltd T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  48. 12.8.5 F. Hoffmann-La Roche Ltd Recent Developments
  49. 12.9 Celgene Corp
  50. 12.9.1 Celgene Corp Company Information
  51. 12.9.2 Celgene Corp Business Overview
  52. 12.9.3 Celgene Corp Revenue in T Cell Surface Glycoprotein CD3 Epsilon Business (2021-2026)
  53. 12.9.4 Celgene Corp T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  54. 12.9.5 Celgene Corp Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst